on ABIVAX (EPA:ABVX)
Abivax strengthens its team and announces its financial results for H1 2026
Abivax has unveiled its latest financial results for the first half of 2026. The company has €402.4 million in cash, figures increased by a €767.1 million fundraising in July, guaranteeing its financial strength until the end of 2029.
Two strategic appointments have been announced. Chris Rabbat becomes Chief Medical Officer, succeeding Fabio Cataldi, and will bring his expertise in inflammatory diseases. Tim Kelly is appointed Chief Technology Officer, to enhance the company's commercial and technological output.
The repurchase of the Royalties Certificates significantly reduced future liabilities, resulting in a charge of €43.2 million. R&D expenditures increased, particularly concerning obefazimod. Abivax is preparing for the potential commercialization of this treatment.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news